HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Milrinon
Primacor · Milirinone · Milrinone USP · YM-018 · Minong · Milrila · Corotrop · win47203
Identifikatoren & physikalische Daten
| CAS No. | 78415-72-2 |
|---|---|
| Summenformel | C12H9N3O |
| Durchschnittliche Molmasse | 211,22 g/mol |
| Monoisotopische Masse | 211,07456191 g/mol |
| SMILES | Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1 |
| InChIKey | PZRHRDRVRGEVNW-UHFFFAOYSA-N |
| PubChem CID | 4197 |
| ChEMBL | CHEMBL189 |
| ChEBI | CHEBI:50693 |
| EC No. | 278-903-6 |
| DTXSID | DTXSID5023324 |
| Lokaler Name | Milrinon |
Chemische & physikalische Eigenschaften
| XLogP | 0 |
|---|---|
| Polarare Oberfläche (TPSA) | 65,8 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 1 |
| Schwere Atome | 16 |
| Formalladung | 0 |
| Komplexität | 419 |
| Arzneimittel | PharmaceuticalsPharmaceuticals -> Listed in ZINC15 |
| LogP (Verteilungskoeffizient) | 0.40.42 |
| Löslichkeit | <1 mg/mL2.09e-01 g/LDMSO: >10 mg/mLSoluble in DMSO. Insoluble in water. |
| Human Drugs | Pharmaceuticals |
| Schmelzpunkt | >300 °C> 300 °C>3000C |
| Physical Description | Solid |
| Collision Cross Section | 157.1 Ų [M+H]+ [CCS Type: DTBuffer gas: N2Ionization: APCI+Dataset: TOXCASTSource Identifier: DTXSID5023324]150.4 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| Siedepunkt | 350.9°C (rough estimate) |
| Dichte | 1.1922 (rough estimate) |
| Brechungsindex | 1.5700 (estimate) |
| Lagerbedingungen | 2-8°C |
| Aggregatzustand | powder |
| pKa (Säurekonstante) | 7.21±0.10(Predicted) |
| Farbe | off-white |
| Merck | 14,6197 |
| Stabilität | Stable. Incompatible with strong oxidizing agents. |
| InChI | InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16) |
| InChIKey | FYEJSUDMDUIMKJ-UHFFFAOYSA-N |
| SMILES | C1(C)NC(=O)C(C#N)=CC=1C1C=CN=CC=1 |
| CAS Datenbank | 78415-72-2(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH301+H311+H331 (38.4%): Toxic if swallowed, in contact with skin or if inhaled [Danger Acute toxicity, oralacute toxicity, dermalacute toxicity, inhalation]P261, P262, P264, P270, P271, P280, P301+P316, P302+P352, P304+P340, P316, P321, P330, P361+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 73 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 3 (100%) |
| Unerwünschte Wirkungen | The most feared adverse effect of milrinone is its potential to induce hemodynamic changes and arrhythmias. Milrinone may cause ventricular tachyarrhythmia, leading to cardiac ischemia or sudden cardiac death. These changes are not shown to follow a dose-dependent relationship. Milrinone can cause an increase in venous vessel capacitance, leading to decreased preload and manifesting as headaches, syncope, and severe hypotension. Unlike tachyarrhythmias, hypotension occurs in a dose-dependent relationship. |
| Toxizitätsübersicht | Cardiovascular toxicity is primarily seen in chronically milrinone patients and manifests as tachyarrhythmias and sudden cardiac death. At high dosing, patients may also experience hypotension and syncope. Milrinone had a previous use as an oral formulation for outpatient use in patients with NYHA class III and IV chronic heart failure (CHF) to improve symptoms and decrease the frequency of hospital admissions. However, this practice was discontinued following the PROMISE trial in 1991 due to safety concerns. This double-blinded clinical trial assessed patients with CHF class III/IV placed on milrinone or placebo and ended early due to increased mortality in the milrinone group secondary to ventricular tachyarrhythmias and sudden cardiac death. |
| Wassergefährdungsklasse (WGK) | 3 |
| UN-Transportnummer | UN 2811 6.1/PG 3 |
| Zollcode | 29337900 |
| RTECS-Nr. | DW1762000 |
| R-Sätze (R) | 23/24/25-26/27/28 |
| Gefahrensymbole | T,T+ |
| Sicherheitshinweise (S) | 36/37/39-45-22 |
| Gefahrenklasse | 6.1(b)Acute Tox. 3 Oral |
| Verpackungsgruppe | III |
| Lagerklasse | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
Anwendungen & Verwendung
Beschreibung
Milrinone, an inhibitor of phosphodiesterase selective for fraction III PDE, exerts a positive inotropic effect on the heart as well as a peripheral vasodilatory effect. Milrinone given intravenously produces significant improvements on cardiac output, pulmonary capillary wedge pressure and vascular resistance without significant effects on the heart rate.
Verwenden
It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. Milrinone inhibits the action of phosphodiesterase-3 preventing degradation of cAMP. The corresponding increase in cAMP levels leads to increased activation of protein kinase A. It is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity.